These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 9819030)

  • 1. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII.
    Hoffman M; Monroe DM; Roberts HR
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S61-5. PubMed ID: 9819030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A possible mechanism of action of activated factor VII independent of tissue factor.
    Monroe DM; Hoffman M; Oliver JA; Roberts HR
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S15-20. PubMed ID: 9819024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
    Hoffman M; Monroe DM
    Dis Mon; 2003 Jan; 49(1):14-21. PubMed ID: 12525825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. General haemostatic agents--fact or fiction?
    Hedner U
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
    Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M
    Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant activated factor VII as a universal haemostatic agent.
    Hedner U
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S147-52. PubMed ID: 9819047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
    Hoffman M; Monroe DM
    Semin Hematol; 2001 Oct; 38(4 Suppl 12):6-9. PubMed ID: 11735103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
    Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
    Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First 20 years with recombinant FVIIa (NovoSeven).
    Hedner U; Lee CA
    Haemophilia; 2011 Jan; 17(1):e172-82. PubMed ID: 20609014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor.
    Stewart AJ; Hanley JP; Ludlam CA
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S93-5. PubMed ID: 9819036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cell-based model of thrombin generation.
    Roberts HR; Hoffman M; Monroe DM
    Semin Thromb Hemost; 2006 Apr; 32 Suppl 1():32-8. PubMed ID: 16673264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa.
    Veldman A; Hoffman M; Ehrenforth S
    Curr Med Chem; 2003 May; 10(10):797-811. PubMed ID: 12678684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of tissue factor:factor VIIa-catalyzed factor IX and factor X activation by TFPI and TFPI constructs.
    Peraramelli S; Thomassen S; Heinzmann A; Rosing J; Hackeng TM; Hartmann R; Scheiflinger F; Dockal M
    J Thromb Haemost; 2014 Nov; 12(11):1826-37. PubMed ID: 25163770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study.
    Spira J; Plyushch O; Zozulya N; Yatuv R; Dayan I; Bleicher A; Robinson M; Baru M
    Haemophilia; 2010 Nov; 16(6):910-8. PubMed ID: 20491957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency.
    Ingerslev J; Holm M; Christiansen K; Knudsen L; Négrier C
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S129-34. PubMed ID: 9819044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with activated factor VII: focus on safety aspects.
    Roberts HR
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S115-8. PubMed ID: 9819041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The tissue factor/factor VIIa/factor Xa complex: a model built by docking and site-directed mutagenesis.
    Norledge BV; Petrovan RJ; Ruf W; Olson AJ
    Proteins; 2003 Nov; 53(3):640-8. PubMed ID: 14579355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future possibilities in the regulation of the extrinsic pathway: rFVIIa and TFPI.
    Hedner U; Erhardtsen E
    Ann Med; 2000 Dec; 32 Suppl 1():68-72. PubMed ID: 11209985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group.
    Poon MC; d'Oiron R
    Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S55-68. PubMed ID: 10850567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.